These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 18008332)

  • 1. Involvement of decreased Galectin-3 expression in the pathogenesis and progression of prostate cancer.
    Merseburger AS; Kramer MW; Hennenlotter J; Simon P; Knapp J; Hartmann JT; Stenzl A; Serth J; Kuczyk MA
    Prostate; 2008 Jan; 68(1):72-7. PubMed ID: 18008332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of the PKB/Akt pathway in histological benign prostatic tissue adjacent to the primary malignant lesions.
    Merseburger AS; Hennenlotter J; Simon P; Müller CC; Kühs U; Knüchel-Clarke R; Moul JW; Stenzl A; Kuczyk MA
    Oncol Rep; 2006 Jul; 16(1):79-83. PubMed ID: 16786126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and nuclear localization of ErbB3 in prostate cancer.
    Koumakpayi IH; Diallo JS; Le Page C; Lessard L; Gleave M; Bégin LR; Mes-Masson AM; Saad F
    Clin Cancer Res; 2006 May; 12(9):2730-7. PubMed ID: 16675564
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
    Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
    Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues.
    Petraki CD; Gregorakis AK; Papanastasiou PA; Karavana VN; Luo LY; Diamandis EP
    Prostate Cancer Prostatic Dis; 2003; 6(3):223-7. PubMed ID: 12970725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Higher tumor to benign ratio of the androgen receptor mRNA expression associates with prostate cancer progression after radical prostatectomy.
    Rosner IL; Ravindranath L; Furusato B; Chen Y; Gao C; Cullen J; Sesterhenn IA; McLeod DG; Srivastava S; Petrovics G
    Urology; 2007 Dec; 70(6):1225-9. PubMed ID: 18158066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of the matriptase inhibitor HAI-2 during prostate cancer progression.
    Bergum C; List K
    Prostate; 2010 Sep; 70(13):1422-8. PubMed ID: 20687215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Expression of galectin 3 and Sambucus nigra agglutinin and their clinicopathological significance in benign and malignant lesions of stomach].
    Zhou JP; Yang ZL; Liu DC; Zhou JP
    Zhonghua Wei Chang Wai Ke Za Zhi; 2009 May; 12(3):297-300. PubMed ID: 19434543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential expression of galectins in normal, benign and malignant prostate epithelial cells: silencing of galectin-3 expression in prostate cancer by its promoter methylation.
    Ahmed H; Banerjee PP; Vasta GR
    Biochem Biophys Res Commun; 2007 Jun; 358(1):241-6. PubMed ID: 17481580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6, IL-10 and HSP-90 expression in tissue microarrays from human prostate cancer assessed by computer-assisted image analysis.
    Cardillo MR; Ippoliti F
    Anticancer Res; 2006; 26(5A):3409-16. PubMed ID: 17094460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant expression of cystatin C in prostate cancer is associated with neuroendocrine differentiation.
    Jiborn T; Abrahamson M; Gadaleanu V; Lundwall A; Bjartell A
    BJU Int; 2006 Jul; 98(1):189-96. PubMed ID: 16831167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease.
    Laderach DJ; Gentilini LD; Giribaldi L; Delgado VC; Nugnes L; Croci DO; Al Nakouzi N; Sacca P; Casas G; Mazza O; Shipp MA; Vazquez E; Chauchereau A; Kutok JL; Rodig SJ; Elola MT; Compagno D; Rabinovich GA
    Cancer Res; 2013 Jan; 73(1):86-96. PubMed ID: 23108139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCAR1 expression in prostate cancer: association with 16q23 LOH status, tumor progression and EGFR/KAI1 staining.
    Fromont G; Vallancien G; Validire P; Levillain P; Cussenot O
    Prostate; 2007 Feb; 67(3):268-73. PubMed ID: 17192874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression.
    Madigan MC; Kingsley EA; Cozzi PJ; Delprado WJ; Russell PJ; Li Y
    Cancer Immunol Immunother; 2008 Sep; 57(9):1367-79. PubMed ID: 18273614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Group IIA phospholipase A as a prognostic marker in prostate cancer: relevance to clinicopathological variables and disease-specific mortality.
    Mirtti T; Laine VJ; Hiekkanen H; Hurme S; Rowe O; Nevalainen TJ; Kallajoki M; Alanen K
    APMIS; 2009 Mar; 117(3):151-61. PubMed ID: 19245588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hormonal regulation of beta2-adrenergic receptor level in prostate cancer.
    Ramberg H; Eide T; Krobert KA; Levy FO; Dizeyi N; Bjartell AS; Abrahamsson PA; Taskén KA
    Prostate; 2008 Jul; 68(10):1133-42. PubMed ID: 18454446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD147, MMP-1, MMP-2 and MMP-9 protein expression as significant prognostic factors in human prostate cancer.
    Zhong WD; Han ZD; He HC; Bi XC; Dai QS; Zhu G; Ye YK; Liang YX; Qin WJ; Zhang Z; Zeng GH; Chen ZN
    Oncology; 2008; 75(3-4):230-6. PubMed ID: 18852494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The involvement of altered corticotropin releasing factor receptor 2 expression in prostate cancer due to alteration of anti-angiogenic signaling pathways.
    Tezval H; Jurk S; Atschekzei F; Serth J; Kuczyk MA; Merseburger AS
    Prostate; 2009 Mar; 69(4):443-8. PubMed ID: 19058138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer.
    Edwards J; Traynor P; Munro AF; Pirret CF; Dunne B; Bartlett JM
    Clin Cancer Res; 2006 Jan; 12(1):123-30. PubMed ID: 16397033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fascin regulates prostate cancer cell invasion and is associated with metastasis and biochemical failure in prostate cancer.
    Darnel AD; Behmoaram E; Vollmer RT; Corcos J; Bijian K; Sircar K; Su J; Jiao J; Alaoui-Jamali MA; Bismar TA
    Clin Cancer Res; 2009 Feb; 15(4):1376-83. PubMed ID: 19228738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.